Truist Financial Increases Inspire Medical Systems (NYSE:INSP) Price Target to $54.00

Inspire Medical Systems (NYSE:INSP) had its target price increased by Truist Financial from $50.00 to $54.00 in a report issued on Thursday, MarketBeat.com reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s price objective indicates a potential upside of 6.87% from the company’s current price.

INSP has been the topic of several other reports. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Robert W. Baird dropped their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Royal Bank Of Canada downgraded Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a report on Monday, June 15th. Oppenheimer reiterated a “market perform” rating on shares of Inspire Medical Systems in a research report on Monday, June 15th. Finally, Mizuho lowered their target price on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $81.26.

Inspire Medical Systems Stock Down 2.0%

Shares of NYSE INSP opened at $50.53 on Thursday. The firm’s 50-day simple moving average is $44.36 and its 200 day simple moving average is $58.80. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 11.25, a price-to-earnings-growth ratio of 5.22 and a beta of 0.71. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. Wellington Management Group LLP acquired a new stake in Inspire Medical Systems during the 4th quarter worth $203,929,000. Wasatch Advisors LP raised its position in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares during the last quarter. Morgan Stanley lifted its stake in shares of Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares during the period. Deerfield Management Company L.P. lifted its stake in shares of Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the period. Finally, State Street Corp boosted its position in shares of Inspire Medical Systems by 2.3% in the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after purchasing an additional 22,843 shares during the last quarter. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.